Drugs / TAcs
Trials 0
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Comparator or background therapy1 trial | ||||||
| Phase 2 | NCT03378076 Comparator | Dec 2017 → Mar 2018 | osteoarthritis, knee | Pacira Pharmaceuticals, Inc | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | TAcs | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03378076 ↗ |
| Known as | Triamcinolone Acetonide Crystalline Suspension (TAcs) | “Triamcinolone Acetonide Crystalline Suspension (TAcs)” NCT03378076 ↗ |
| Route | Other | “received concurrent single intra-articular injections of TA-ER 32 mg or TAcs 40 mg into each knee” PMID 31662801 ↗ Oct 2019 |